FDG-PET in Hodgkin lymphoma

Summary

The high negative predictive value of FDG-PET in therapy control of Hodgkin lymphoma is proven by the data acquired up to now. Thus, the analysis of the HD15 trial has shown that consolidation radiotherapy might be omitted in PET negative patients after effective chemotherapy. Further response adapted therapy guided by PET seems to be a promising approach in reducing the toxicity for patients undergoing chemotherapy. The criteria used for the PET interpretation have been standardized by the German study groups for Hodgkin lymphoma patients and will be reevaluated in the current studies.

Zusammenfassung

Der hohe negativ prädiktive Wert der FDG-PET in der Therapiekontrolle des Hodgkin-Lymphoms kann bei aktueller Datenlage als gesichert gelten. In der HD15-Studie wurde bei negativer PET nach Chemotherapie erfolgreich von der konsolidierenden Bestrahlung des Restgewebes abgesehen. Beim Einsatz der PET zur individuell adaptierten Therapie wird von deutschen Studiengruppen die klinische Konsequenz aus einem negativen PET-Befund gezogen. In den laufenden Studien wird die weitere Toxizitätsreduktion für PET-negative Patienten unter Chemotherapie untersucht. Die Kriterien zur Beurteilung der PET sind für die deutschen Studiengruppen einheitlich und werden im Rahmen der Studien reevaluiert.

Keywords

PET - Hodgkin lymphoma - response-adapted design - chemotherapy - radiotherapy

Schlüsselwörter

PET - Hodgkin-Lymphom - individualisierte Therapie - Chemotherapie - Radiotherapie

• Literatur

• 1 Aleman BM, van den Belt-Dusebout AW, Klokman WJ. et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439.
• 2 Beyer T, Pietrzyk U, Knoess C. et al. Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging. Nuklearmedizin 2008; 47: 73-79.
• 3 Bhatia S, Robinson LL, Oberlin O. et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-751.
• 4 Bucerius J, Herkel C, Joe AY. et al. ¹⁸F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma - An analysis of 193 patient studies. Nuklearmedizin 2006; 45: 105-110.
• 5 Buchmann I, Hansen T, Brochhausen C. et al. FDG-PET in the initial staging of squamous cell oesophageal carcinoma. Nuklearmedizin 2006; 45: 235-241.
• 6 Cheson BD, Pfistner B, Juweid ME. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
• 7 DeWit M, Bohuslavizki KH, Buchert R. et al. ¹⁸FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
• 8 Diehl V. Hodgkin disease-from pathology specimen to cure. N Engl J Med 2007; 357: 1968-1971.
• 9 Diehl V, Franklin J, Pfreundschuh M. et al. Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. N Engl J Med 2003; 348: 2386-2395.
• 10 Döbert N, Kovacs AF, Menzel C. et al. FDG uptake after intraarterial chemotherapy in head and neck cancer. Nuklearmedizin 2006; 45: 243-247.
• 11 Dose-Schwarz J, Mahner S, Schirrmacher S. et al. Detection of metastases in breast cancer patients - Comparison ofFDG PET with chest X-ray, bone scintigraphy and ultrasound of the abdomen. Nuklearmedizin 2008; 47: 97-103.
• 12 Franzius C, Dietlein M, Biermann M. et al. Procedure guideline for radioiodine therapy and ¹³¹I whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin 2007; 46: 224-231.
• 13 Franzius C, Juergens KU, Schober O. Is PET/CT necessary in paediatric oncology?. Eur J Nucl Med Mol Imaging 2006; 33: 960-965.
• 14 Gallamini A, Hutchings M, Avigdor A. et al. Early interim PET scan in Hodgkin Lymphoma: where do we stand?. Leuk Lymphoma 2008; 49: 659-662.
• 15 Gallamini A, Hutchings M, Rigacci L. et al. Early interim 2-[¹⁸F]-fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from ajoint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
• 16 Jost L. Hodgkin's disease: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007; 18 (Suppl. 02) ii53-ii54.
• 17 Juergens KU, Oei ML, Weckesser M. et al. Whole-body imaging of oncologic patients using 16-channel PET-CT - Evaluation of an IV contrast enhanced MDCT protocol. Nuklearmedizin 2008; 47: 30-36.
• 18 Juweid ME, Stroobants S, Hoekstra OS. et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571-578.
• 19 Hutchings M, Loft A, Hansen M. et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin Lymphoma. Blood 2006; 107: 52-59.
• 20 Kobe C, Dietlein M, Franklin J. et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008 DOI 10.1182/blood-2008-06-155820
• 21 Körholz D, Claviez A, Hasenclever D. et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004; 216: 150-156.
• 22 Körholz D, Kluge R, Wickmann L. et al. The importance of ¹⁸F-fluorodeoxy-D-2-glucose positron emission tomography for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence. Onkologie 2003; 26: 489-493.
• 23 Krause BJ, Beyer T, Bockisch A. et al. FDG-PET/ CT in oncology-German Guideline. Nuklearmedizin 2007; 46: 291-301.
• 24 Krohn T, Kaiser H-J, Gagel B. et al. 3D volume and SUV analysis ofoncological PET studies. Nuklearmedizin 2007; 46: 141-148.
• 25 Krüger S, Pauls S, Mottaghy FM. et al. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma. Nuklearmedizin 2007; 46: 239-243.
• 26 La Fougère P, fluger T, Schneider V. et al. Resta- ging of patients with lymphoma. Nuklearmedizin 2008; 47: 37-42.
• 27 Markova J, Skopalova M, Kobe C. et al. FDG-PET for Assessment of early therapy response after 4 cycles of chemotherapy in advanced stage Hodgkin Lymphoma. Ann Oncol. 2008 19. iv135.
• 28 Martinez M-J, Bercier Y, Schwaiger M. et al. PET/ CT BiographTM Sensation 16 - Performance improving using faster electronics. Nuklearmedizin 2006; 45: 126-133.
• 29 Naumann R, Beuthien-Baumann B, Reiss A. et al. Substantial impact ofFDG PET imaging on the therapy decision inpatients with early-stage Hodgkin's lymphoma. Br J Cancer 2004; 90: 620-625.
• 30 Pauls S, BuckA K, Hohl K. et al. Improved noninvasive T-Staging in non-small cell lung cancer by integrated ¹⁸F-FDG PET/CT. Nuklearmedizin 2007; 46: 9-14.
• 31 Picardi M, De Renzo A, Pane F. et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tompgra-physcans. Leuk Lymphoma 2007; 48: 1721-1727.
• 32 Rigacci L, Vitolo U, Nassi L. et al. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007; 86: 897-903.
• 33 Römer W, Nömayr A, Greess H. et al. Restrospective interactive rigid fusion of ¹⁸F-FDG-PET and CT: Additional diagnostic information in melanoma patients. Nuklearmedizin 2006; 45: 88-95.
• 34 Schaefer NG, Taverna C, Strobel K. et al. Hodgkin Disease: Diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed?. Radiology 2007; 244: 257-262.
• 35 Schicha H, Schober O. Nuklearmediz. In: Basiswissen und klinische Anwendung. 5. Aufl. Stuttgart: Schattauer; 2003: p81f.
• 36 Spaepen K, Stroobants S, Dupont P. et al. Can positron emission tomography with [¹⁸F]-fluorode- oxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol 2001; 115: 272-278.
• 37 Stauss J, Franzius C, Pfluger T. et al. Guidelines for ¹⁸F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging 2008; 35: 1581-1588.
• 38 Weihrauch MR, Re D, Scheidhauer K. et al. Thoracic positron emission tomography using ¹⁸F-fluo- rodeoxyglucose for the evaluation of residual mediastinal Hodgkin's disease. Blood 2001; 98: 2930-2934.
• 39 Wolz G, Nömayr A, Hothorn T. et al. Anatomical accuracy of interactive and automated rigid registration between X-ray CT and FDG-PET. Nuklearmedizin 2007; 46: 43-48.
• 40 Zinzani PL, Tani M, Fanti S. et al. Early positron emission tomographyrestaging: apredictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17: 1296-1300.